Abstract: A tyrosine-substituted hirudin analog has antithrombogenic activity. Further simultaneous reaction at native tyrosine residues is prevented by mutation at those sites to encode nonreactive amino acids. Several novel strategies for coupling the hirudin analog to solid surfaces while simultaneously conserving antithrombogenic activity are disclosed.
Type:
Grant
Filed:
June 19, 1995
Date of Patent:
November 17, 1998
Assignee:
Baxter International Inc.
Inventors:
Cecilia S. L. Ku, Richard Johnson, Julian P. Breillatt, Jr.